Clinical Trials Logo

Advanced/Metastatic Solid Tumors clinical trials

View clinical trials related to Advanced/Metastatic Solid Tumors.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05718895 Recruiting - Clinical trials for Advanced/Metastatic Solid Tumors

A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors

CLINCH
Start date: March 27, 2023
Phase: Phase 1
Study type: Interventional

This is an Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients with Advanced/metastatic Solid Tumors

NCT ID: NCT05614258 Recruiting - Clinical trials for Advanced/Metastatic Solid Tumors

Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors

Start date: February 13, 2023
Phase: Phase 1
Study type: Interventional

ADG206 is an activatable prodrug form of a fully human monoclonal antibody (mAb) of the immunoglobulin G1 (IgG1) subclass that specifically targets cluster of differentiation 137 (CD137) (also known as 4-1BB) as a co-stimulatory receptor agonist for the treatment of advanced malignancies.

NCT ID: NCT05607498 Recruiting - Clinical trials for Advanced/Metastatic Solid Tumors

First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

Start date: March 1, 2023
Phase: Phase 1
Study type: Interventional

For solid tumors and lymphoma, respectively: This study is to evaluate the safety and tolerability of EMB-07 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-07 will also be assessed.

NCT ID: NCT05514444 Recruiting - Neoplasms Clinical Trials

Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)

Start date: September 25, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of MK-4464 as monotherapy and in combination with pembrolizumab in participants with advanced/metastatic solid tumors.

NCT ID: NCT05405595 Recruiting - Clinical trials for Advanced/Metastatic Solid Tumors

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Start date: June 15, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b/2, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of ADG126-pembrolizumab combination regimens in patients with advanced/metastatic solid tumors.

NCT ID: NCT04645069 Recruiting - Clinical trials for Advanced/Metastatic Solid Tumors

ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors

Start date: March 15, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

ADG126, ADG126 in Combination with anti-PD1 antibody, and ADG126 in Combination with ADG106 in Patients with Advanced/Metastatic Solid Tumors .

NCT ID: NCT03526835 Recruiting - Colorectal Cancer Clinical Trials

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Start date: May 2, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the RP2D of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck cancer. The study will further assess the safety, tolerability, PK, PD, immunogenicity, and anti-tumor activity of MCLA-158.